Search

Breakthrough results in European multicenter trial on acute promyelocytic leukemia (APL): no more chemotherapy?

APL is a rare, yet aggressive, subtype of acute myeloid leukemia (AML) characterized by a maturation arrest of white blood cell precursors in the marrow, leading to a shortage of normal white cells and platelets in the blood, which is…

Read more

Dr A van Hylckama Vlieg Announced Winner of the first EHA-ISTH Joint Fellowship

The award of EUR 72,000 over two years is intended to support the study of the physiology of bleeding, coagulation or thrombosis. Dr.

Read more

EHA2025 delegate services [draft]

EHA is pleased to introduce delegate services for the upcoming EHA2025 Congress—services that registered participants can use prior, during, or after the event. Special airline fare

Enjoy a discounted flight rate and join us in Milan.

Read more

EHA2023 Gallery

We extend our gratitude to the esteemed Faculty, delegates, and industry partners for their valuable contributions to the EHA2023 Hybrid Congress.

Read more

Abstract & Clinical Case Submission and Travel Grant

Abstract and clinical case procedureAbstract submission is closed

The official abstract submission closed on August 1, 2023 (23:59).

Read more

5th European CAR T-cell Meeting

The European Hematology Association (EHA) and the EBMT are excited to announce the 5th edition of the jointly organized European CAR T-cell Meeting.

Read more

‘Rare Cancers in all EU policies’: Prof Elizabeth Macintyre expresses strong EHA support for the Rare Cancers Europe agenda

On September 28, EHA President Elizabeth Macintyre addressed an audience that included Members of the European Parliament, and officials of the European Commission and the European Medicines Agency, as well as members of the Rare Cancers Europe (RCE) partnership.

Read more